Biotech RadarJobs updated

COMPANY

Foresee Pharmaceuticals

foreseepharma.com ↗ · Mid-Atlantic

FDA-approved therapeutic company Clinical Phase 3

Keywords: long-acting injectable Prostatic Neoplasms Prostate Cancer Asthma (Diagnosis) Pulmonary Function Moderate-to-Severe Asthma Fanconi Anemia Severe to Critical COVID 19 With Associated ARDS FP-025 (MMP-12 inhibitor) FP-025 Mirivadelgat Triptorelin FP-014 FP-045 FP-020

Profile checked Oct 10, 2026

15Trials (company is sponsor)1FDA records (2 yrs)

Timeline

  1. Trial start Phase 2: Effect of Linvemastat in Patients With Partially Controlled Asthma (syMMPonia) source ↗
  2. FDA FDA Original approval: CAMCEVI ETM (leuprolide mesylate) — NDA219745, Aug 25, 2025. Applicant at approval: Foresee Pharmaceuticals Co., Ltd. source ↗
  3. Trial start Phase 3: Efficacy, Safety, and Pharmacokinetics of FP-014, 11.25 mg in Patients With Advanced Prostate Cancer source ↗
  4. Trial start Phase 3: Efficacy, Safety, and Pharmacokinetics of FP-014, 22.5 mg in Patients With Advanced Prostate Cancer source ↗
  5. Trial start Phase 2: Study to Evaluate Safety and Efficacy of Mirivadelgat in PH-ILD (Windward) source ↗
  6. Trial start Phase 1: Safety, Tolerability, and Pharmacokinetics, of Single and Multiple Ascending Doses of FP-020 in Healthy Adult Volunteers source ↗
  7. Trial start Phase 1/Phase 2: A Dose Escalation Study of FP-045 in Patients With Fanconi Anemia source ↗
  8. Trial start Phase 3: Efficacy, Safety, and Pharmacokinetics of Leuprolide Mesylate in Subjects With Central Precocious Puberty source ↗
  9. Trial start 2: A Phase 2/3 Study to Evaluate FP-025 in Patients With Severe to Critical COVID 19 source ↗
  10. Trial start Phase 2: The Effect of FP-025, on Allergen-induced Airway Responses in Mild Eosinophilic House Dust Mite (HDM)-Allergic Asthma. source ↗
  11. Trial start Phase 1: Multiple-Dose, Dose-Escalation Study to Evaluate the Safety/Tolerability and Pharmacokinetics of FP-045 source ↗
  12. Trial start Phase 3: Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate (LMIS 25 mg) in Subjects With Prostate Cancer source ↗
  13. Trial start 1: A Phase 1, Pharmacokinetics of the MMP-12 Inhibitor FP-025 After Multiple Oral Ascending Doses in Healthy Subjects source ↗
  14. Trial start Phase 3: Open-Label Safety Extension Study in Patients Who Have Previously Participated and Have Benefited From LMIS 50 mg source ↗
  15. Trial start 1: Phase 1 Safety, Tolerability and Pharmacokinetics (PK) Study of FP-025 in Healthy Volunteers source ↗
  16. Trial start Phase 3: Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate in Subjects With Advanced Prostate Carcinoma source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 15

RecordTitlePhaseStatusStartPrimary completion
NCT06475781Study to Evaluate Safety and Efficacy of Mirivadelgat in PH-ILD (Windward)Phase 2RecruitingMar 1, 20252028-02 (estimated)
NCT07191535Effect of Linvemastat in Patients With Partially Controlled Asthma (syMMPonia)Phase 2Not yet recruitingMar 1, 2027Jan 1, 2028 (estimated)
NCT05493709Efficacy, Safety, and Pharmacokinetics of Leuprolide Mesylate in Subjects With Central Precocious PubertyPhase 3CompletedJun 2, 2023Dec 7, 2025 (actual)
NCT06795191Efficacy, Safety, and Pharmacokinetics of FP-014, 22.5 mg in Patients With Advanced Prostate CancerPhase 3WithdrawnJun 1, 2025Nov 30, 2027 (estimated)
NCT06795178Efficacy, Safety, and Pharmacokinetics of FP-014, 11.25 mg in Patients With Advanced Prostate CancerPhase 3WithdrawnJul 1, 2025Dec 31, 2027 (estimated)
NCT04522375A Dose Escalation Study of FP-045 in Patients With Fanconi AnemiaPhase 1/Phase 2WithdrawnJun 30, 20232025-06 (estimated)
NCT06334211Safety, Tolerability, and Pharmacokinetics, of Single and Multiple Ascending Doses of FP-020 in Healthy Adult VolunteersPhase 1CompletedApr 16, 2024Sep 20, 2024 (actual)
NCT03858686The Effect of FP-025, on Allergen-induced Airway Responses in Mild Eosinophilic House Dust Mite (HDM)-Allergic Asthma.Phase 2CompletedJul 2, 2018Dec 30, 2022 (actual)
NCT04750278A Phase 2/3 Study to Evaluate FP-025 in Patients With Severe to Critical COVID 192TerminatedApr 6, 2021Apr 18, 2022 (actual)
NCT02238834Phase 1 Safety, Tolerability and Pharmacokinetics (PK) Study of FP-025 in Healthy Volunteers1Completed2015-062018-12 (actual)
NCT03686930Multiple-Dose, Dose-Escalation Study to Evaluate the Safety/Tolerability and Pharmacokinetics of FP-045Phase 1CompletedFeb 22, 2018May 27, 2018 (actual)
NCT03261999Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate (LMIS 25 mg) in Subjects With Prostate CancerPhase 3CompletedSep 26, 2017Nov 19, 2018 (actual)
NCT02712320Open-Label Safety Extension Study in Patients Who Have Previously Participated and Have Benefited From LMIS 50 mgPhase 3Completed2016-022017-05 (actual)
NCT02234115Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate in Subjects With Advanced Prostate CarcinomaPhase 3Completed2014-08Aug 30, 2016 (actual)
NCT03304964A Phase 1, Pharmacokinetics of the MMP-12 Inhibitor FP-025 After Multiple Oral Ascending Doses in Healthy Subjects1CompletedJul 21, 2017Jun 1, 2018 (actual)

FDA records (last 2 years)

Connect

See your connections at Foresee Pharmaceuticals on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-12

Feedback